Canaccord Genuity initiated coverage of TransMedics Group (NASDAQ:TMDX) with a “buy” rating and price target of $37. The stock closed at $28.88 on May 24.
Mackie Research Capital downgraded Medicure (TSXV:MPH) to “hold from “buy” and cuts its price target to $6.50 from $7.60 after the company reported weaker than expected first quarter results. The stock closed at $5.99...
OncoSec Medical (NASDAQ:ONCS) dosed the first patient in a trial assessing a triple drug combination, which includes OncoSec’s TAVO, in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer...
The FDA approved REGENXBIO’s (NASDAQ:RGNX) ZOLGENSMA for the treatment of spinal muscular atrophy (SMA) in pediatric patients who are less than two years of age. Caused by a genetic defect in the SMN1 gene, SMA is...
Neovasc (NASDAQ:NVNC) reported positive long term safety and efficacy data for its Reducer device in 50 patients suffering from refractory disabling angina. Neovasc’s Reducer relives angina symptoms by altering blood...
Iovance Biotherapeutics (NASDAQ:IOVA) LN-145 received FDA breakthrough therapy designation in recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy. Designed to...
Paradigm launched coverage of Cansortium (CSE:TIUM) with a “buy” rating and a price target between $2.40 and $3.40. The stock closed at $1.59 on May 23.
H.C. Wainwright raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $25 from $15 after assessing the value of the company’s recently-received new dosing regimen patent. The stock closed at $6.49 on May...
Canopy Growth (TSX:WEED; NYSE: CGC) acquired This Works in an all-cash transaction for £43 million. British-based This Works offers a range of high-quality natural skincare and sleep solution products, including deep...